Table 1.
Patient access by the DH for England and Wales
| Drug | Company | Indication under consideration | Details of PAS and of NICE decision including the PAS | PPRS categoriz-ation | TA number | Date of publication of TA or FAD |
|---|---|---|---|---|---|---|
| Velcade (bortezomib) | Johnson & Johnson | Multiple myeloma | Restricted NICE recommendation on condition that company would refund cost of treating non-responders | Financially-based scheme: Response scheme | TA129 | October 2009 |
| Lucentis (ranibizumab) | Novartis | Macular degeneration (age related) | Restricted NICE recommendation on condition that company would agree to pay drug cost for treating patients who required more than 14 injections per eye (2 years treatment). Cost effectiveness for treatment beyond this period not established. | Financially-based scheme: Free stock | TA155 | August 2008 |
| Tarceva (erlotinib) | Roche | Non small cell lung cancer | Restricted NICE recommendation on condition that the overall costs of treatment would be no more than docetaxel for same indication. | Financially-based scheme: Simple discount | TA162 | November 2008 |
| Stelera (ustekinumab) | Janssen-Cilag | Psoriasis | Restricted NICE recommendation based on establishment of cost effectiveness by setting price for dose for patients who weigh more than 100 kg to the lower dose for patients below this weight (essentially provide two vials for the price of one) | Financially-based scheme: Free stock | TA180 | September 2009 |
| Erbitux (cetuximab) | Merck Serono | First line metastatic colorectal cancer | Restricted NICE recommendation based on establishement of cost effectiveness following a 16% rebate of the amount of cetuximab used. The scheme requires that patients are treated according to the final NICE guidance and that data should be provided to the manufacturer to show that the NICE guidance has been followed. | Financially-based scheme: Rebate | TA176 | August 2009 |
| Revlimid (lenalidomide) | Celgene | Multiple mylenoma in people who have received one prior therapy | Approved by NICE on condition that company agreed to pay drug cost for patients who require more than 26 cycles of 28 days (normally 2 years of treatment) | Financially-based scheme: Free stock | TA171 | June 2009 |
| Tyverb (lapatinib) | GSK | Previously treated advanced or metastatic breast cancer | Not recommended for use by NICE as cost effectiveness, including PAS, not established. Terms of proposed scheme acquisition cost for all qualifying patients for up to 12 weeks to be paid by manufacturer. Responding patients continuing treatment to be fully funded by the NHS. | Financially-based scheme: Response scheme | Second FAD | June 2010 |
| Sutent (sunitinib) | Pfizer | Gastrointestinal stromal tumours | Restricted NICE recommendation on condition that company cover costs for first treatment cycle | Financially-based scheme: Free stock | TA179 | September 2009 |
| Sutent (sunitinib) | Pfizer | First line treatment for patients with advanced and/or metastatic renal cell carcinoma | Restricted NICE recommendation on condition that company cover costs for first treatment cycle | Financially-based scheme: Free stock | TA169 | March 2009 |
| Nexavar (sorafenib) | Bayer | Advanced hepatocellular carcinoma | Not recommended by NICE as cost effectiveness not established. Under proposed PAS, Bayer would provide every fourth pack free of charge or rebate its cost to the NHS. | Financially-based scheme: Free stock or rebate | TA 189 | May 2010 |
| Nexavar (sorafenib) | Bayer | Used to treat advanced or metastatic renal cell carcinoma | Not recommended for use by NICE as cost effectiveness, with PAS, not established. Under proposed PAS, company to supply first pack of sorafenib free to NHS per patient. | Financially-based scheme: Free stock | TA178 | August 2009 |
| Avastin (bevacizumab) | Roche | Used to treat advanced or metastatic renal cell carcinoma | Not recommended for use by NICE as cost effectiveness, with PAS, not established. Under proposed PAS company rebate of cost of drug after 10 g given to a patient in 12 month period and rebate of cost of IFN-α when given with Avastin. | Financially-based scheme: Rebate | TA178 | August 2009 |
| Avastin (bevacizumab) | Roche | Metastatic colorectal cancer | Not recommended for use by NICE as cost effectiveness, with PAS, not established. Company offering to provide Avastin at a fixed cost, even though quantity is dependent upon patient weight. Roche also proposed to provide oxaliplatin free of charge for patients taking Avastin, or to reimburse the hospitals. Further offer to cover the cost of treatment with Avastin for patients needing the drug for more than 12 months (approx. 12–15% of patients go beyond a 12 month course). | Financially-based scheme: Rebate | TA118 | January 2007 |
| Cimzia (certolizumab pegol) | UCB | Advanced rheumatoid arthritis | Recommended for restricted use by NICE contingent upon a PAS in which company must cover the cost of the first 3 months of therapy (10 syringes). | Financially-based scheme: Free stock | TA186 | February 2010 |
| Yondelis (trabectedin) | PharmaMar/Johnson and Johnson | Advanced soft tissue carcinoma | Recommended for restricted use by NICE if the company meets acquisition cost if treatment is needed beyond five cycles | Financially-based scheme: Free stock | TA185 | February 2010 |
Sources:Scrip, NICE website and Department of Health.